Based on these transcriptomic results, suppression of CCN2, FGFR2, and SELE may inhibit tumor proliferation, metastasis, or angiogenesis, while upregulation of CDH1 and CXCL10 could enhance cellular adhesion and antitumor immune responses, offering promising avenues for therapeutic intervention. The gene discussed is SELE; the disease is neoplasm.